Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S. Kwatra SG, et al. Among authors: weidinger s. Acta Derm Venereol. 2024 May 6;104:adv18452. doi: 10.2340/actadv.v104.18452. Acta Derm Venereol. 2024. PMID: 38708991 Free PMC article.
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.
Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C, Romero W. Gooderham MJ, et al. Among authors: weidinger s. Dermatol Ther (Heidelb). 2024 Aug;14(8):2285-2296. doi: 10.1007/s13555-024-01200-5. Epub 2024 Jul 2. Dermatol Ther (Heidelb). 2024. PMID: 38954384 Free PMC article.
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, Elmaraghy H, Atwater AR, Pierce E, Xu C, Agell H, Gil EG, Simpson E. Guttman-Yassky E, et al. Among authors: weidinger s. J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414-5. doi: 10.1016/j.jaad.2024.12.026. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39733939
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry.
Traidl S, Hollstein MM, Kroeger N, Fischer S, Heratizadeh A, Heinrich L, Kind B, Siegels D, Abraham S, Schäfer T, Augustin M, Harder I, Pinter A, Schäkel K, Wollenberg A, Ertner K, Ramaker-Brunke J, Bong A, Quist S, Gorriahn-Maiterth H, Schenck F, Sticherling M, Effendy I, Schwarz B, Handrick C, Asmussen A, Weidinger S, Schmitt J, Werfel T; TREATgermany Study Group. Traidl S, et al. Among authors: weidinger s. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):136-144. doi: 10.1111/jdv.20042. Epub 2024 Apr 25. J Eur Acad Dermatol Venereol. 2025. PMID: 38661511 Free PMC article.
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, Lynde C, Kataoka Y, Foley P, Wei X, Wong W, Solente AC, Weber C, Adelman S, Davey S, Hurbin F, Rynkiewicz N, Yen K, O'Malley JT, Bernigaud C. Weidinger S, et al. J Allergy Clin Immunol. 2024 Nov 8:S0091-6749(24)01175-8. doi: 10.1016/j.jaci.2024.10.031. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 39522654 Free article.
Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry.
Traidl S, Heinrich L, Siegels D, Heratizadeh A, Kind B, Haufe E, Abraham S, Schäfer T, Augustin M, Harder I, Pinter A, Schäkel K, Wollenberg A, Ertner K, Ramaker-Brunke J, Bong A, Quist S, Gorriahn-Maiterth H, Schenck F, Sticherling M, Effendy I, Schwarz B, Handrick C, Asmussen A, Weidinger S, Schmitt J, Werfel T; TREATgermany study group. Traidl S, et al. Among authors: weidinger s. J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e887-e891. doi: 10.1111/jdv.19979. Epub 2024 Mar 28. J Eur Acad Dermatol Venereol. 2024. PMID: 38545850 No abstract available.
399 results